HALIOSEEK
LIVE

Serial Number

79213961

Owner

HalioDx

Attorney

Kevin A. Thompson

Filing Date

May 5, 2017

Add to watchlist:

No watchlists yet
View on USPTO

HALIOSEEK Trademark

Serial Number: 79213961 • Registration: 5592381

HALIOSEEK is a trademark filed by HalioDx on May 5, 2017. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

HalioDx (6 trademarks)

163 Avenue de Luminy,
F-13288 Marseille Cédex 09 , FR

Entity Type: 34

VERACYTE (7 trademarks)

PARC SCIENTIFIQUE DE LUMINY

Entity Type: 34

Trademark Details

Filing Date

May 5, 2017

Registration Date

October 30, 2018

Published for Opposition

August 14, 2018

Cancellation Date

May 16, 2025

Goods & Services

Software for use in the clinical diagnosis, prognosis, monitoring, prediction of response to treatments and on-going evaluation, analysis and study of a cancer, tumor or equivalent medical condition; application software in the field of biology for use in the clinical diagnostic, prognosis, monitoring, prediction of response to treatments and on-going evaluation, analysis and study of a cancer, tumor or equivalent medical condition

Pharmaceutical products for use in vitro testing, for use in the clinical diagnosis, prognosis, monitoring, prediction of response to treatments and on-going evaluation, analysis and study of a cancer, tumor or equivalent medical condition; chemical preparations for medical and pharmaceutical use for use in vitro testing, for use in the clinical diagnostic, prognosis, monitoring, prediction of response to treatments and on-going evaluation, analysis and study of a cancer, tumor or equivalent medical condition; biological reagents for medical use for providing information on diagnostics or identification of biological systems; biological reagents for medical use providing information on diagnostics or identification of biological systems; immunological reagents for medical use; biological reagents for medical diagnosis; medical diagnostic kits comprising reagents and assays for testing tissue samples; biological reagents for medical research; biological reagents for medical use; biological reagents for clinical diagnosis

Medical analysis services, namely, analysis of tumor, cancer or equivalent medical condition; medical assistance; heath care services; medical therapeutic services; medical diagnostics, diagnostics in the field of medicine; genetic analysis services for medical purposes

Scientific research and development; clinical trial services, namely, intervening in the process of clinical trial services in assessment of biomarkers or signatures; tests in laboratories, namely analysis of biological mechanisms of actions, biomarkers and signatures for research in biology purposes; development of quality control testing methods for others; research, development, technical design, testing, consultancy and analysis services in the field of immunology; research and development of antibodies, therapeutic products, vaccines, immunotherapy treatments and diagnostic products; research services in the field of genome and immune index analysis; design and development of software in the field of biology

Medical apparatus, instruments and equipment for medical analysis, namely autostainers, scanners; medical apparatus and instruments for providing information on diagnostics or identification of biological systems, namely, medical testing devices and diagnostic apparatus for detecting, analysing or assessing a cancer, tumor or equivalent medical condition; medical instruments for cancer cell detection

Filing History

TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Jan 16, 2026 INTR
NEW REPRESENTATIVE AT IB RECEIVED
Aug 21, 2025 NREP
CANCELLED SECTION 71
May 16, 2025 C71T
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Oct 30, 2023 REM3
CHANGE OF NAME/ADDRESS REC'D FROM IB
Feb 12, 2022 ADCH
FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 1, 2019 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Feb 7, 2019 FICS
FINAL DISPOSITION PROCESSED
Feb 7, 2019 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jan 30, 2019 FICR
REGISTERED-PRINCIPAL REGISTER
Oct 30, 2018 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 14, 2018 NPUB
PUBLISHED FOR OPPOSITION
Aug 14, 2018 PUBO
NOTIFICATION PROCESSED BY IB
Aug 11, 2018 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jul 25, 2018 OPNS
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 25, 2018 NONP
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jul 25, 2018 OP2R
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 10, 2018 CNSA
REFUSAL PROCESSED BY IB
Jun 23, 2018 RFNP
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 13, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 12, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 12, 2018 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 3, 2018 GNRN
NON-FINAL ACTION E-MAILED
May 3, 2018 GNRT
NON-FINAL ACTION WRITTEN
May 3, 2018 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 21, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 21, 2018 CRFA
ASSIGNED TO LIE
Feb 19, 2018 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 12, 2018 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 31, 2018 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 31, 2018 REAP
REFUSAL PROCESSED BY IB
Sep 9, 2017 RFNT
APPLICATION FILING RECEIPT MAILED
Aug 19, 2017 MAFR
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 18, 2017 RFCS
REFUSAL PROCESSED BY MPU
Aug 18, 2017 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 17, 2017 RFCR
NON-FINAL ACTION WRITTEN
Aug 16, 2017 CNRT
ASSIGNED TO EXAMINER
Aug 15, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 15, 2017 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Aug 10, 2017 REPR